Bristol Myers Receives a Sell from BMO Capital

By Ryan Adsit

In a report released today, Alex Arfaei from BMO Capital assigned a Sell rating to Bristol Myers (NYSE: BMY), with a price target of $49. The company’s shares closed yesterday at $65.11, close to its 52-week high of $65.50.

According to TipRanks.com, Arfaei is a 3-star analyst with an average return of 3.6% and a 57.3% success rate. Arfaei covers the Healthcare sector, focusing on stocks such as Kindred Biosciences, Merck & Company, and Eli Lilly & Co.

Bristol Myers has an analyst consensus of Hold, with a price target consensus of $60.20.

Bristol Myers’ market cap is currently $106.8B and has a P/E ratio of 23.68. The company has a book value ratio of 7.2641.

Based on the recent corporate insider activity of 52 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.